Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-24 am EDT 		5-day change 1st Jan Change
4,134 JPY 0.00% Intraday chart for Takeda Pharmaceutical Company Limited +0.10% +1.97%
May. 16 Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment MT
May. 15 Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company appears to be poorly valued given its net asset value.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.58 times its estimated earnings per share for the ongoing year.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TAKEDA PHARMACEUTICAL COMPANY LIMITED Stock Takeda Pharmaceutical Company Limited
+1.97% 41.29B
B+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 728B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 603B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 279B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 244B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 207B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 205B
A+
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. Ratings Takeda Pharmaceutical Company Limited